According to documents submitted by NEUROONE MEDICAL TECH to the U.S. Securities and Exchange Commission, the company has restated its financial data for the first quarter of 2026 to correct a previous overstatement of revenue by approximately $500,000.

This restatement involves adjustments to the first quarter's revenue, aiming to correct accounting errors in prior reports. Through this action, the company ensures the accuracy and compliance of its financial statements to meet regulatory requirements. Corrections to financial data typically reflect an internal review and strengthening of the company's financial reporting processes. When assessing company performance, investors should pay attention to the impact such restatements may have on historical financial results and future expectations.